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Abstract
African green monkeys (AGM) and other natural hosts for simian immunodeficiency virus (SIV) do not develop an AIDS-like
disease following SIV infection. To evaluate differences in the role of SIV-specific adaptive immune responses between
natural and nonnatural hosts, we used SIVagmVer90 to infect vervet AGM and pigtailed macaques (PTM). This infection results
in robust viral replication in both vervet AGM and pigtailed macaques (PTM) but only induces AIDS in the latter species. We
delayed the development of adaptive immune responses through combined administration of anti-CD8 and anti-CD20
lymphocyte-depleting antibodies during primary infection of PTM (n=4) and AGM (n=4), and compared these animals to
historical controls infected with the same virus. Lymphocyte depletion resulted in a 1-log increase in primary viremia and a
4-log increase in post-acute viremia in PTM. Three of the four PTM had to be euthanized within 6 weeks of inoculation due
to massive CMV reactivation and disease. In contrast, all four lymphocyte-depleted AGM remained healthy. The lymphocyte-
depleted AGM showed only a trend toward a prolongation in peak viremia but the groups were indistinguishable during
chronic infection. These data show that adaptive immune responses are critical for controlling disease progression in
pathogenic SIV infection in PTM. However, the maintenance of a disease-free course of SIV infection in AGM likely depends
on a number of mechanisms including non-adaptive immune mechanisms.
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Introduction
Although it is not known when SIV was first introduced into
African nonhuman primates, it is widely believed that African
monkey and ape species coevolved with SIV infection probably for
tens of thousands of years [1,2]. In contrast, Asian nonhuman
primates and humans encountered the virus much more recently
[2,3]. Despite these differences, SIV infections in nonhuman
primates and HIV in humans follow a similar pattern of viremia:
an initial burst of viremia during primary infection followed by a
partial containment and establishment of a plateau or set point
viremia [4,5,6]. Additionally, the level of viremia in African
monkeys, natural hosts of SIV, and Asian monkeys, nonnatural
hosts of SIV infection is similar [7,8,9,10]. Given the similarities in
viral load, however, the course of infection and its consequences
differ between natural and nonnatural hosts [11,12,13]. Most
natural hosts such as AGM appear to peacefully coexist with the
SIV infection while macaques generally develop overt signs of
illness, immune failure and AIDS [14]. However, recent findings
indicate that some natural hosts like chimpanzees may develop an
AIDS-like disease when infected with SIV [15].
These differences in pathogenic consequences of infection prompt
speculation about the mechanisms that enable African primate
species to cope with SIV infection without developing disease. AGM
provide a dramatic contrast to the apparently irrevocable pathway to
immune failure seen in SIV-infected macaques and HIV-infected
humans. At least two fundamental characteristics of SIV infection of
natural host species that appear to distinguish them from pathogenic
infections include the lack of chronic immune activation and the
paucity of CCR5+ CD4+ target cells [11,16,17]. These differences
suggest that natural hosts may have developed a complex arsenal of
protective mechanisms to cope with the pathogenic consequences of
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CD8+ T cells and humoral immune responses, have also been
observed in SIV-infected natural hosts either at comparable or lower
magnitude than in pathogenic SIV and HIV infection
[18,19,20,21,22,23,24]. However, the ultimate role of adaptive
immune responses in the protection against disease progression in
AGM and other natural hosts of SIV remain elusive.
An ideal setting to study the role of adaptive immune responses is
to utilize the same virus strain of SIV in two different host species that
would respond with similar dynamics of viremia but disparate disease
outcome. Previously, it was shown that SIVagmVer90 can induce AIDS
in pigtailed macaques (Macaca nemestrina) but not in vervet AGM
(Chlorocebus pygerythrus) [25]. In fact, SIVagmVer90 infection induces an
AIDS-like disease in PTM, similar to that observed in SIVmac251-
infection in rhesus monkeys. Critically for the present study, set point
viremia in SIVagmVer90-infection of PTM and AGM is similar. This
observation confirms a characteristic finding in natural hosts:
disparate pathogenic outcomes despite a similar magnitude of
viremia as seen in nonnatural hosts. In fact, in natural hosts the
magnitude of viremia varies widely, without any clinical consequenc-
es [7]. In contrast, the extent of viremia is an excellent predictor of
disease progression in pathogenic models such as macaques and
humans [26,27,28].
Here, we utilized the administration of antibodies to deplete both
CD8+ lymphocytes and B cells during primary SIVagmVer90 infection
in AGM and PTM to delay cellular and humoral SIV-specific
immune responses. These studies underlined the critical role of
adaptive immune responses in viral control in nonnatural hosts like
PTM. In contrast, the absence of clinical signs of disease in AGM
suggested that the maintenance of a disease-free courseof infection in
natural hosts does not solely depend on adaptive immune responses.
Results
Depletion of CD8+ and CD20+ lymphocytes in vervet
AGM and PTM
To better understand the role of adaptive immune responses
during the early stages of SIV infection in pathogenic and non-
pathogenic models of SIV infection, we initiated the depletion of
CD8+ and CD20+ lymphocytes prior to infection with SIV. Six
vervet AGM and six PTM received five doses of humanized anti-
CD8a cM-T807 monoclonal antibody (mAb) on days 0, 3, 7, 10
and 14 and three doses of anti-CD20 human mAb on days 27, 14
and 35. Four lymphocyte-depleted animals of each species were
also inoculated intravenously with SIVagmVer90 [25] on day 0, and
two AGM and PTM served as uninfected controls.
The treatment with lymphocyte depleting mAb resulted in a
transient depletion of both CD8+ T cells and CD20+ B cells from
peripheral blood in the AGM (Fig. 1A and C). A comparable
period of lymphocyte depletion, 6 and 14 weeks for CD8+ T cells
and B cells, respectively, was also observed in the uninfected
control AGM (A9 and A23). The SIV-infected AGM had a
median CD8+ T cell depletion of 3.5 weeks (range: 2–6 weeks) and
a median B cell depletion of 12 weeks (range: 4–18 weeks). AGM
A7 showed the earliest resurgence of both CD8+ T and B cells (3
and 4 weeks, respectively). Vervet AGM harbor two distinct
subsets of CD8+ T cells: CD8aa homodimer and CD8ab
heterodimer expressing cells [18]. Despite a lower expression of
the CD8 molecule on CD8aa T cells, administration of the cM-
T807 mAb affected both CD8+ T cell subsets (data not shown).
The cells that first reappeared after CD8+ T cell depletion were
mainly CD8aa+ T cells. Since depletion of peripheral blood
lymphocyte subsets does not reflect depletion in tissues, we
performed flow cytometric analyses for CD8+ and CD20+
lymphocyte subsets in bronchoalveolar lavage samples (BAL)
and lymph node biopsies. A shorter duration of CD8+ T cell
depletion was observed in BAL and lymph nodes of SIV-infected
AGM where CD8+ T cells rebounded at week three (Fig. 1B and
data not shown). This was associated with a transient increase in
double negative (CD42 CD82) T cells in BAL consistent with
down-modulation or masking of the CD8 molecule on T cells
(data not shown). The SIV negative control animals were CD8+
lymphocyte-depleted in BAL and lymph nodes throughout week
four post depletion. Four of the lymphocyte-depleted AGM had a
long lasting depletion of B cells in peripheral blood for 13–16
weeks and two AGM (A7 and A13) had a shorter depletion of 4
and 10 weeks post infection (p.i.) (Fig. 1C). A similar transient
depletion of B cells was also observed in lymph node sections at
one and four weeks p.i. (data not shown and Fig. 2A–C).
Four of the six lymphocyte-depleted PTM showed an efficient and
long lasting depletion of CD8+ T cells and B cells (P31, P23, P27,
P35) (Fig. 1D, E and F) .D e p l e t i o no fb o t hC D 8 + T cellsand B cells
was irreversible in three of the SIV-inoculated PTM (P23, P27, and
P35). Each of these PTM rapidly developed disease and had to be
euthanized by 6–7 weeks. Transient depletion was observed in one of
the SIV-infected PTM, P24, and one uninfected animal, P33. Both
PTM had a depletion of CD8+ T cells for two weeks and a partial
depletion of CD20 cells with a reappearance of B cells at week 8 post
depletion (Fig. 1D and F). The uninfected PTM P31 had a long
lasting B cell depletion of 20 weeks and a CD8+ T cell depletion of 5
weeks. Analysis of CD20 expression in peripheral lymph node
sections correlated with the flow cytometric analysis of peripheral
blood. Depletion of B cells in the long-term depleted PTM was very
efficient in lymph node sections (Fig. 2D–F). This contrasted with
incomplete depletion in lymph node biopsies collected at one and
four weekspost depletion from P24 (Fig.2G–I),theoneSIV-infected
PTM with incomplete peripheral depletion.
CD8+ T cell and CD20+ lymphocyte depletion increases
peak viremia in PTM but not AGM
CD8+ and CD20+ lymphocyte depletion had only a brief effect
on the plasma RNA viral load in AGM. The viral load followed a
Author Summary
Simian immunodeficiency virus (SIV) is a naturally occur-
ring infection in a wide range of African nonhuman
primates, including African green monkeys (AGM), which
generally results in a clinically inapparent infection. In
contrast, SIV infection of Asian nonhuman primates such
as macaques can result in an AIDS-like disease similar to
that observed in humans infected with human immuno-
deficiency virus (HIV). This different pathogenic outcome
occurs despite similar levels of viremia. In order to evaluate
the contribution of adaptive immune responses to these
different outcomes, we transiently inhibited the genera-
tion of CD8+ and CD20+ lymphocyte-mediated immune
responses in vervet AGM and pigtailed macaques (PTM)
during primary SIV infection. PTM experienced higher
viremia and accelerated progression to disease, whereas
AGM showed only a short prolongation of peak viremia
but exhibited no signs of illness. These results demonstrate
that protection against development of disease in AGM
does not solely rely on adaptive immune responses. Future
efforts should aim to determine the underlying mecha-
nisms that enable natural hosts to cope with SIV infection
and to apply these findings to develop new treatment
modalities for humans infected with HIV.
SIVagm Infection in AGM and PTM
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control AGM that were inoculated with the same virus (Fig. 3A).
The peak SIV viral load was similar between CD8+ and CD20+
lymphocyte-depleted AGM and control AGM (median: 0.79610
7
SIV RNA copies/ml in the depleted AGM versus 1.47610
7 SIV
RNA copies/ml in the control AGM; P=0.200 Fig. 3B). There
was however a trend towards a prolongation of peak viremia in the
CD8+ and CD20+ lymphocyte depleted AGM. The median viral
load was higher at three weeks p.i. in the antibody-treated AGM
than in the historic controls (lymphocyte-depleted: 7.22610
5 SIV
RNA copies/ml versus control: 0.35610
5 SIV RNA copies/ml;
P=0.057). This trend was not maintained and differences in
viremia between the two groups of AGM vanished at week six p.i.
(median: 1.14610
5 SIV RNA copies/ml versus 0.645610
5 SIV
RNA copies/ml; P=0.688). To confirm the plasma viral load
results, we assessed SIV expressing cells by in situ hybridization of
peripheral lymph nodes sampled from AGM at one and four
weeks p.i. (Fig. 3C and 4). As shown in Fig. 3C, the number of
SIV positive cells in lymph node biopsies from control or antibody-
treated AGM at one or four weeks p.i. did not differ significantly
(P=0.486 and P=0.183).
As reported previously [29], the kinetics of viremia in PTM and
vervet AGM inoculated with SIVagmVer90 is similar. As expected,
all control PTM experienced a peak of viremia at 7–10 days p.i.
followed by a decline to setpoint viremia (Fig. 3D). In contrast to
the AGM, we detected a significantly higher SIV plasma viral
RNA copy number in CD8+ and CD20+ lymphocyte-depleted
PTM than in control SIV infected PTM (median; lymphocyte-
depleted: 8.79610
8 versus control: 0.66610
8, P=0.029; Fig. 3E).
Plasma viral load remained significantly higher throughout the
remainder of their disease course (P=0.029 at 3 and 6 weeks p.i.).
The viral load in the inefficiently-depleted PTM (P24) decreased to
a level seen at the high end of the range of the historic control
PTM. The higher viral load in the lymphocyte-depleted PTM was
confirmed by analysis of SIV expression in lymph node sections.
As shown in Fig. 3F and 4, there was a trend to higher levels of
SIV+ cells in PTM lymph nodes collected at one week p.i.
(P=0.057) and a significantly higher number of SIV+ cells at four
weeks p.i. (P=0.029).
CD8+ and CD20+ lymphocyte depletion affects survival
of SIV-infected PTM but not AGM
All of the SIV-infected AGM remained healthy throughout the
original observation period of 50 weeks p.i. and beyond despite
efficient lymphocyte depletion in the mAb-treated group (Fig. 5A).
In striking contrast to the AGM, CD8+ and CD20+ lymphocyte
depletion in PTM resulted in an accelerated disease progression
compared with historical control PTM infected with the same
inoculum (Fig. 5B; log rank test; P=0.007). Three of the four
PTMs with almost complete lymphocyte depletion developed
respiratory distress that necessitated euthanasia by six weeks p.i.
The fourth animal had only a transient CD8+ and CD20+
lymphocyte depletion and experienced similar clinical signs during
the primary stages of infection but made a partial clinical recovery.
This animal subsequently experienced episodes of vasculitis
associated with infarction of the skin, weight loss, poor appetite
and diarrhea that eventually led to euthanasia at 18 weeks p.i.
Pathologic evaluation of the three PTM euthanized early in the
infection were remarkably similar, and included severe lymphoid
depletion, severe vasculitis with pulmonary edema and cytome-
Figure 1. CD8+ T cell and CD20+ B cell depletion in AGM and PTM. Anti-CD8 antibody administration-induced depletion of CD8+
lymphocytes in peripheral blood lymphocytes (PBL) and bronchoalveolar lavage (BAL) in AGM (A, B) and PTM (D, E). Anti-CD20 antibody
administration induced depletion of B cells in PBL of vervet AGM (C) and of PTM (F). Animals that received anti-CD8 and anti-CD20 antibodies but
were not inoculated with SIV are shown with black symbols. Animals that received anti-CD8 and anti-CD20 antibodies and were inoculated with
SIVagmVer90 are shown in color symbols (red for AGM, blue for PTM). The black arrows in panels A and D indicate the injection of the anti-CD8a mAb
cM-T807. The black arrows in panels C and F indicate the injection of the anti-CD20 mAb Rituximab.
doi:10.1371/journal.ppat.1000691.g001
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PLoS Pathogens | www.plospathogens.org 3 December 2009 | Volume 5 | Issue 12 | e1000691Figure 3. CD8+ and CD20+ lymphocyte depletion has a greater effect on SIV peak viremia and lymphatic tissue viral load in PTM
than in AGM. Plasma SIV RNA copies/ml are shown for vervet AGM (A, B) and for PTM (D, E). Number of SIV RNA expressing cells in lymph node
biopsies of anti-CD8 and anti-CD20 treated and historic control AGM (C) and PTM (F) at one and four weeks p.i. The median number of SIV positive
cells is given for each animal and was quantified for six high power fields (HPF). CD8+ and CD20+ lymphocyte-depleted animals are plotted in color
symbols (red symbols for vervet AGM and blue symbols for PTM) and historic control animals in black symbols.
doi:10.1371/journal.ppat.1000691.g003
Figure 2. Only partial depletion of B cells in lymphatic tissues of CD8+ and CD20+ lymphocyte-depleted AGM but not of PTM.
Immunohistochemical (IHC) detection of CD20+ B cells in sequential lymph node biopsies from a representative vervet AGM (A346) collected pre-
inoculation (A), one week p.i. (B), and four weeks p.i. (C). Representative IHC staining for CD20 is shown on two PTM with different clinical courses.
PTM P27 was representative of the pattern seen in the three PTM that showed efficient depletion of CD20+ B cells at one week p.i. that was
irreversible at four weeks p.i. (D, E, and F). PTM P24 only had a partial depletion of CD20+ B cells at one week p.i. and near normal CD20+ B cell levels
at four weeks p.i. (G, H, and I).
doi:10.1371/journal.ppat.1000691.g002
SIVagm Infection in AGM and PTM
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consistent with disseminated cytomegalovirus (CMV) infection.
SIV-specific in situ hybridization showed high levels of SIV-
expression in all lymphoid tissues and in the brain or meninges
consistent with uncontrolled SIV replication (data not shown).
CD8+ and CD20+ lymphocyte depletion in the context of
SIV infection induces massive CMV reactivation in PTM
To confirm the pathologic findings and to examine the effect of
CD8+ and CD20+ lymphocyte depletion on CMV reactivation,
we assayed CMV DNA in the plasma of both the AGM and PTM
by quantitative PCR. As shown in Fig. 6B and D, SIV infection
alone did not result in significant activation of CMV either in
AGM or PTM. However, CMV activation was observed in the
majority of the animals that were CD8+ and CD20+ lymphocyte-
depleted as indicated by detectable CMV DNA in plasma (Fig. 6A
and C) regardless of whether they were also infected with SIV.
Reactivation of CMV was transient in the SIV infected and CD8+
and CD20+ lymphocyte-depleted AGM. In contrast, massive
reactivation of CMV (up to 10
6 copies/ml of plasma) was observed
in three of the CD8+ and CD20+ lymphocyte depleted and SIV-
inoculated PTM. The PTM with the shortest duration of CD8+ T
cell and B cell depletion transiently controlled CMV replication by
week 12 but CMV DNA in plasma was detectable again prior to
death. Reactivation of CMV in lymphocyte-depleted monkeys
shows that control of CMV is dependent on functional CD8+ and
CD20+ lymphocytes, as observed in AGM. PTM however
appeared to be too compromised either by high level SIV viremia
and/or lack of CD8+ and CD20+ lymphocytes to mount an
effective immune response against CMV.
Massive loss of CD4+ T cell in SIV-infected PTM
The majority of CD4+ T cells in vervet AGM coexpress the
CD8aa homodimer [18]. Administration of the anti-CD8a mAb
therefore had a potential depleting effect on CD4+ T cells.
Absolute CD4+ T cell counts in the blood declined with a median
of 246% (range: 259% to +6%) following administration of the
anti-CD8a mAb, regardless of inoculation with SIV (Fig. 7A).
Interestingly, CD4+ T cell levels did not return to pre-treatment
values, but remained relatively stable in the AGM with exception
of A346. This animal experienced an abrupt decline in peripheral
blood CD4+ T cell numbers after week 14 that coincided with a
slight increase in plasma viremia. Viremia subsequently decreased
and the animal remained free from clinical signs of disease
throughout one year of follow up, despite a very low frequency of
CD4+ T cells (,5 cells/ml).
In contrast to the vervet AGM, CD4+ T cells in PTM do not
express the CD8aa homodimer. Therefore, administration of the
anti-CD8a antibody did not affect CD4+ T cell counts in the non-
infected mAb treated PTM (Fig. 7C). The relatively stable
number of peripheral blood CD4+ T cells in AGM was not
observed for the lymphocyte-depleted PTM where SIV infection
resulted in an abrupt decline in peripheral blood CD4+ T cells in
the first 2 weeks of infection (Fig. 7C). CD4+ T cell levels
continued to decline in three of the animals (P24, P27, and P35).
PTM P23 showed a less dramatic loss of CD4+ T cells than the
other three lymphocyte-depleted PTM (Fig. 7C). Similar kinetics
and extent of CD4+ T cell decline were observed in untreated
control PTM infected with SIV (Fig. 7D). CD4+ T cell decline
was less severe in the two PTM with lower viremia (P9665, P9663).
These two animals also showed the longest survival (.105 weeks)
[13].
Increased naive to memory CD4+ T cell ratio and CD4+ T
cell proliferation in PTM but not AGM
The decline of CD4+ T cells in pathogenic models of AIDS
infected with a CCR5-tropic virus is mainly due to a loss of
memory CD4+ T cells [6,30]. To assess the extent of memory
CD4+ T cell depletion, we evaluated the ratio of naı ¨ve to memory
CD4+ T cells in PTM and AGM. We observed an initial loss of
Figure 4. CD8+ and CD20+ lymphocyte depletion in SIVagmVer90-infected PTM results in enhanced virus replication in contrast to
AGM. Representative SIV-specific in situ hybridization of lymph nodes collected at one and four weeks p.i. from a vervet AGM (left) and PTM (right).
Top panels show samples from CD8+ and CD20+ lymphocyte-depleted animals and bottom panels show samples from historical control animals.
Active viral replication in SIV positive cells is marked in black color.
doi:10.1371/journal.ppat.1000691.g004
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ratio of naı ¨ve to memory CD4+ T cells than before infection
(Fig. 8A, B) in all but one SIV-infected AGM. The non-infected
lymphocyte-depleted AGM experienced a similar increase in the
ratio of naı ¨ve to memory CD4+ T cells as SIV-infected AGM
(Fig. 8A). In AGM, memory CD4+ T cells express higher levels of
CD8a than naive CD4+ T cells (data not shown) and therefore
may be preferentially depleted by the anti-CD8 mAb. After the
transient loss of memory CD4+ T cells, the naı ¨ve to memory
CD4+ T cell ratio recovered to levels comparable to pre-infection
ratios, with the exception of A7. A7 recovered from the initial loss
of memory CD4+ T cells to a higher, but nevertheless stable ratio
of naı ¨ve to memory CD4+ T cells. As described above, one of the
AGM (A346) suffered an almost complete loss all of its peripheral
blood CD4+ T cells (Fig. 7A). The loss of CD4+ T cells also
included a precipitous decline of naive CD4+ T cells as indicated
by the decline in the naive to memory CD4+ T cell ratio indicated
(Fig. 8A).
In contrast to the effects on the CD4+ T cell subset in vervet
AGM, a much more obvious but also transient increase in the
naive to memory CD4+ T cell ratio was observed in three of four
CD8+ and CD20+ lymphocyte-depleted, SIV-infected PTM
(Fig. 8C). The short term depleted PTM, P24, only showed a
minor increase in the naı ¨ve to memory CD4+ T cell ratio with a
subsequent slow decline to low levels just prior to death. In
contrast, a much more muted decline in memory CD4+ T cells
was observed in SIV-infected control PTM (Fig. 8D).
A more severe pathogenic SIV infection is generally associated
with an increased turnover of CD4+ T cells. The increased
proliferation of CD4+ T cells can be directly assessed by an
increase in Ki-67 expression on memory CD4+ T cells. We
therefore evaluated the proliferation of memory CD4+ T cells in
both AGM and PTM (Fig. 9). As expected, a vigorous
proliferation of memory CD4+ T cells was seen in both the
lymphocyte-depleted and the historical control SIV-infected PTM
(Fig. 9C and D). In contrast to the pathogenic SIV infection, we
only observed a marginal increase in proliferation of memory
CD4+ T cells in both of the two SIV-infected groups of AGM
(Fig. 9A and B). The brief increase of memory CD4+ T cell
proliferation in both SIV negative AGM and PTM was likely the
result of compensatory homeostatic mechanisms in response to the
depletion of CD8+ T cells (Fig 9A and B).
B cell depletion induces a delay in SIV-specific antibody
responses but has marginal effect on viremia
Even low numbers of remaining B cells in lymphoid tissue after
CD20+ lymphocyte depletion may support the generation of SIV-
specific antibodies. We therefore evaluated the efficacy of the
inhibition of humoral immune responses by determining the
generation of SIV-specific antibody responses by Western blot and
neutralization assays. Western blot assays of AGM plasma against
whole SIVagmVer90 virus lysate revealed a delay in the development
of SIV-specific antibodies in three of the four lymphocyte-depleted
AGM compared to historical non-depleted control AGM
inoculated with the same virus (Fig. 10A and C). All control
AGM developed SIV-specific antibodies by four to six weeks p.i.
Similarly the inefficiently CD20+ lymphocyte-depleted AGM (A7)
developed SIV-specific antibodies by six weeks p.i. The three long-
term B cell-depleted AGM only seroconverted after week six, and
two animals showed only a weak response to SIV antigen even at
24 weeks post infection.
A more dramatic effect on seroconversion was observed in PTM
that were depleted of CD8+ T cells and CD20+ cells (Fig. 10B).
Only the PTM (P24) transiently depleted of CD8+ T cells and B
cells developed SIV-specific antibody responses at four weeks p.i.
The three other B cell-depleted PTM did not develop any SIV
specific antibodies. All of the historic control PTM developed
variable levels of SIV-specific antibody responses by four to six
weeks p.i. (Fig. 10D). We attempted to confirm these data using
SIVagmVer90 envelope-pseudotyped HIV particles in a single round
neutralizing antibody (Ab) assay [31]. However, SIVagmVer90
appeared to be highly resistant to neutralization and therefore we
were unable to detect neutralizing Ab in any of the AGM in this
study. However, using a tissue culture lab-adapted SIVmac251 strain,
we observed a delay in the generation of neutralizing Ab in AGM
that had been well-depleted of B cells compared to the historic non-
depleted SIV infected control AGM (Fig. 11A). The appearance of
neutralizing Ab had no consistent effect on the magnitude of plasma
viremia in either of these AGM (Fig. 11B and C).
Discussion
Soon after the discovery of AIDS viruses it became apparent
that natural hosts of SIV do not generally develop immunodefi-
ciency in association with SIV infection, whereas these viruses
readily induce disease in Asian nonhuman primates and humans
[8,12,32,33,34]. However, the mechanisms employed by these
primates to avoid the pathogenic consequences of SIV-infection
remain unclear.
Figure 5. Reduced survival of SIVagmVer90-infected CD8+ and
CD20+ lymphocyte-depleted PTM in contrast to disease-free
survival of AGM. Kaplan-Meier survival curves for CD8+ and CD20+
lymphocyte-depleted and historic control vervet AGM (A) and PTM (B)
are shown. Differences in survival were determined by log rank test.
doi:10.1371/journal.ppat.1000691.g005
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SIV-specific adaptive immune responses in a nonnatural host and
natural host of SIV infection, PTM and vervet AGM, respectively.
To do this, we evaluated the effect of antibody-mediated temporal
inhibition of cellular and humoral immune responses during
primary infection with the uncloned SIV virus, SIVagmVer90,i n
PTM and AGM. Recent investigations have shown that this virus
does not induce an AIDS-like disease in AGM but is not inherently
nonpathogenic as infection studies in PTM have shown [25]. Here
in this study, temporal inhibition of adaptive immune responses in
primary SIV infection of PTM resulted in an increased peak and
set point viremia and accelerated disease progression similar to
observations recently made in CD8+ lymphocyte-depleted rhesus
macaques infected with pathogenic SIV [35,36,37]. Interestingly,
in the present study and in unpublished observations evaluating
sabaeus AGM (R.C. Zahn et al.), peak viremia was not increased
in lymphocyte-depleted AGM but only a relatively brief
prolongation of peak viremia was observed during primary
infection. The delay in resolution of primary viremia was very
likely due to the inhibition of cellular immune responses since
primary viremia had resolved before the appearance of humoral
immune responses. Also, the eventual generation of humoral
immune responses in B cell-depleted animals following reappear-
ance of these cells did not appear to have a significant influence on
the magnitude of viremia. This observation was recently
confirmed by others when B cell depletion during primary and
chronic SIV infection of AGM did not result in an increased
viremia or clinical signs of illness (personal communications with
Ivona Pandrea). Thus, the data presented here and unpublished
observations using sabaeus AGM (R.C. Zahn et al.) suggest that
cellular immune responses contribute to viral containment in
AGM but humoral immune responses appear to be less critical.
However, in contrast to rhesus monkeys the absence of CD8+
lymphocytes in AGM resulted in a much more subdued impact on
viremia, similar to observations recently made in sooty mangabeys
[38].
Although no overt signs of SIV disease were seen in the
lymphocyte-depleted AGM, the depletion of these cells was
associated with reactivation of CMV. A similar transient
reactivation of CMV without clinical signs was observed in one
of the two PTM that were lymphocyte-depleted but not challenged
with SIV. The most significant signs of pathogenicity were seen in
PTM that were depleted of CD8+ and CD20+ lymphocytes and
inoculated with SIV: in these animals, we observed a massive
increase in plasma CMV DNA copies, precipitous loss of CD4+ T
cells and an increase in naive/memory CD4+ T cell ratio,
indicating a rapid loss of memory CD4+ T cells.
These observations raise a number of questions. Is it possible
that the impairment of adaptive immune responses in AGM was
not of sufficient duration to negatively impact the health of these
animals? Or, is the inherent ability to suppress immune activation
in SIV-infected AGM the critical factor that helps AGM to cope
with chronic SIV infection?
CD8+ lymphocyte depletion in rhesus macaques results in a
significantly enhanced disease progression. However, as recently
shown [35,39,40] and observed here in the PTM depleted of
CD8+ lymphocytes, the fastest disease acceleration is seen in
nonnatural hosts when CD8+ lymphocytes are depleted for at least
the first 4 weeks during primary SIV infection. However, the
CD8+ lymphocyte depletion in most AGM in this study was of
fairly short duration. But even the one relatively long-term CD8+
lymphocyte-depleted AGM (A13; about 6 weeks) did not develop
an AIDS like-disease with rapid disease progression as we have
seen in all rhesus macaques studied so far with a similar length of
Figure 6. CD8+ and CD20+ lymphocyte depletion results in CMV reactivation in AGM and PTM. CMV DNA copies in plasma of vervet
AGM (A) and PTM (C) are shown graphically for animals not infected with SIVagm but depleted of CD8+ and CD20+ lymphocytes (black symbols), and
animals that were depleted of CD8+ and CD20+ lymphocytes and SIVagmVer90-infected (red for vervet AGM, blue for PTM). For comparison, historic
SIV-infected control AGM (B) and PTM (D) that did not receive administrations of mAbs are shown. The median values of six replicates for sequential
plasma samples at each time point from each animal are shown.
doi:10.1371/journal.ppat.1000691.g006
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this study also was only depleted for 2 weeks, but succumbed to
AIDS within 18 weeks p.i.
A number of recent investigations have shown that natural hosts
exhibit a much lower level of immune activation during chronic
viremia compared to nonnatural hosts [16,32]. The low level
immune activation may protect the natural host species from more
aggressive virus replication and the development of an AIDS-like
disease. Recent investigations have shown that short-term immune
activation using LPS or an IL-2/diphtheria toxin fusion protein in
AGM can result in an increased viremia, supporting the notion
that hyperactivation of the immune system plays a role in virus
replication and disease progression [41]. However, these brief in
vivo manipulations had no apparent effect on the health of the
animals. Thus, in vivo manipulations in AGM that are capable of
suppressing adaptive immune responses for a longer duration than
in the present study and/or induce a prolonged immune activation
may result in a different outcome.
In addition, there may be a number of possible caveats in our
study. (1). Since CD4+ T cells in vervet AGM dimly coexpress the
CD8a molecule, administration of the anti-CD8a antibody may
have also affected CD4+ T cell targets and thus limited virus
replication. However, a similar result was recently observed in
sabaeus AGM that did not coexpress the CD8a molecule on
CD4+ T cells (R.C. Zahn et al., unpublished observations). We
also cannot clearly rule out that NK cells that express the CD8a
molecule may contribute to viral containment as these cells are
also depleted by the anti-CD8a antibody. It is also possible that
some of the differences observed in the control group and the
antibody-treated group may be due to utilizing historical controls
for this study. However, both the historical controls and antibody-
treated group were treated identically except for receiving
lymphocyte-depleting antibodies. Finally, it is conceivable that
the combined depletion of CD8+ and CD20+ lymphocytes may
affect AGM and PTM differently. However, to formally rule out
that the antibody treatment may have a more significant
pathogenic effect on PTM we have performed the lymphocyte
depletion experiments as well in SIV-negative AGM and PTM
which both did not exhibit any signs of disease following the
antibody administrations.
Recent investigations have shown that evolutionary adapta-
tions in natural hosts (paucity of CCR5+ cells, decreased immune
activation, and ability to down modulate the CD4 molecule on
CD4+ Tcells) may assist adaptive immuneresponses ormay even
render SIV-specific adaptive immune responses unnecessary
[32,42,43]. In contrast, if the AIDS virus can bypass restriction
Figure 7. CD4+ T cell count changes in PTM and vervet AGM. Effect of CD8+ and CD20+ lymphocyte depletion on absolute CD4+ T cell counts
in peripheral blood of vervet AGM (A) and PTM (C) that were inoculated with SIVagmVer90 (color symbols) or not infected (black symbols). Absolute
CD4+ T cell counts in peripheral blood of historic control vervet AGM (B) and PTM (D) that were inoculated with the same dose of SIVagmVer90 but
were not treated with mAbs are shown for comparison.
doi:10.1371/journal.ppat.1000691.g007
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to be the major defense against uncontrolled virus replication.
However, the eventual failure of viral control is due to inevitable
viral immune escape [44,45]. A sign of the incredible plasticity of
the immune system of natural hosts to cope with SIV infection
was seen in one of the lymphocyte-depleted AGM (A346). This
animal eventually lost all of its peripheral blood CD4+ T cells
(both memory and naı ¨ve cells), suggesting that the virus in this
animal might have changed coreceptor usage (characterization of
coreceptor usage is still ongoing). Even with an almost complete
loss of peripheral blood CD4+ T cells the animal showed no signs
of disease. Recently, a similarly abrupt decline in CD4+ T cells
was observed in another natural host of SIV, sooty mangabeys,
upon emergence of a CXCR4-tropic SIV variant without
inducing disease [46]. This abrupt decline of CD4+ T cells in
sooty mangabeys does not necessarily always depend on
switching the tropism of the virus to CXCR4 [47]. AGM may
be capable of utilizing a large fraction of CD4- T cells, which can
be found in peripheral blood and tissues, as surrogate T helper
cells [43,48].
Investigations into natural hosts of SIV, including AGM, will
allow us to understand how these animals can coexist with SIV
without developing disease. The observations made here and in
sabaeus AGM (R.C. Zahn et al., unpublished observations) suggest
that CD8+ T cell responses participate to some degree in
controlling viral replication in natural hosts. However, the effects
were considerably more limited than observations made in
macaques and it is not clear whether a more long-term increase
in viremia would precipitate disease progression in AGM. Further
investigations are required to assess the relative contribution of
adaptive immune responses versus non-adaptive mechanisms in
the maintenance of an AIDS-free course of infection in natural
host species. Our aim is that these investigations will provide clues
how pathogenic AIDS virus infections could be limited, identify
new therapeutic approaches, and contribute to the development of
a successful HIV vaccine.
Materials and Methods
Ethics statement
All animals were maintained in accordance with the guidelines
of the Committee on the Care and Use of Laboratory Animals
under a NIAID-approved animal study protocol [49], and all
studies and procedures were reviewed and approved by the
Institutional Animal Care and Use Committees of the NIH and
Harvard Medical School.
Figure 8. Increase in naive/memory CD4+ T cell ratio in SIVagmVer90-infected, efficiently CD8+ and CD20+ lymphocyte-depleted
PTM. Ratio of naive to memory CD4+ T cells in peripheral blood of vervet AGM (A) and PTM (C). SIVagmVer90-challenged vervet AGM and PTM are
shown with red and blue symbols, respectively. Animals that received the anti-CD8 and anti-CD20 depleting antibodies but were not inoculated with
SIV are shown in black symbols. The ratio of naive to memory CD4+ T cells is shown for four control SIV-infected vervet AGM (B) and PTM (D) in black
symbols and lines.
doi:10.1371/journal.ppat.1000691.g008
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Animals were inoculated intravenously with SIVagmVer90,a n
isolate from a naturally-infected vervet AGM (Chlorocebus pygery-
thrus) imported from Kenya in 1987 [7]. The virus (SIVagmVer90)
was isolated from the mesenteric lymph nodes of monkey AGM90
by coculture of viably frozen mononuclear cells with pigtailed
macaque peripheral blood mononuclear cells (PBMC). The vervet
AGM utilized for this study were imported from Tanzania and
screened for SIV infection by Western blotting, virus isolation
from PBMC, and plasma viral RNA (vRNA) loads. PTM were
colony bred in North America. All study animals were
seronegative for SIV, respiratory syncytial virus (SRV), and simian
T-cell leukemia virus (STLV-1).
Animal study design
A total of six adult vervet AGM and six adult PTM were
recruited for combined CD8+ and CD20+ lymphocyte depletion
studies. The chimeric anti-human CD8a monoclonal antibody
(mAb), cM-T807 (NIH Nonhuman Primate Reagent Resource)
was administered at 10 mg/kg of body weight subcutaneously on
day 0 (the day of SIV infection) followed by 5 mg/kg intravenous
injections on days 3, 7, 10 and 14. The anti-human CD20 mAb,
RituxanH (Rituximab), purchased from Genentech, Inc. (South
San Francisco, CA), was administered intravenously at 50 mg/kg
of body weight on days 27, 14 and 35. For lymph node biopsies,
animals were sedated with TelazolH. For all other procedures
including brochoalveolar lavage (BAL), phlebotomy and Ab
injections, animals were sedated with ketamine hydrochloride.
Of these twelve treated animals, four AGM and four PTM were
inoculated intravenously with 1,000 50% tissue culture infectious
doses (TCID50) of SIVagmVer90 on day 0. The remaining antibody-
treated animals (two AGM and two PTM) were not infected.
Animals were monitored for 50 weeks following inoculation by
plasma viral load, SIV-specific antibody responses by Western
blot, lymphocyte subsets in the blood, BAL and lymph node
biopsies (22, 1, and 4 weeks p.i.), and clinical evidence of disease.
Animals showing weight loss of greater than 10% of body weight,
diarrhea, or evidence of pneumonia that was unresponsive to
antibiotic or supportive therapy were humanely euthanized and
tissues collected for pathology. An additional four AGM and four
PTM previously inoculated with the same SIVagmVer90 stock and
dose served as historic, untreated controls [7,29].
Figure 9. Ki-67 expression in memory CD4+ T cells from vervet AGM and PTM. Ki-67 expression of CD4+ T cells in peripheral blood of
vervet AGM (A) and PTM (C). SIVagmVer90-challenged vervet AGM and PTM are shown with red and blue symbols respectively. Animals that received
the anti-CD8 and anti-CD20 depleting antibodies but were not inoculated with SIV are shown in black symbols. For comparison, the percentage of Ki-
67+ CD4+ T cells is shown for four control SIV-infected vervet AGM (B) and PTM (D) in black symbols and lines.
doi:10.1371/journal.ppat.1000691.g009
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Plasma levels of viral SIV RNA in PTM and AGM were
measured by a quantitative real-time RT-PCR assay as previously
described [7], using methodology based on the 7700 sequence
detection system (Applied Biosystems, Foster City, CA). Plasma
samples were collected from EDTA-anticoagulant whole blood
and were stored in a 280uC freezer until analysis. Plasma viral
RNA was isolated using a QIAmp viral RNA kit (QIAGEN,
Valencia, CA), and RT-PCR reactions were performed in 96-well
plates.
Measurement of CMV DNA in plasma by real-time PCR
CMV DNA was quantitated in plasma using real-time PCR as
previously described [50]. DNA was extracted from plasma with
the QIAmp DNA Mini Kit (Qiagen, Inc., Valencia, CA). The
rhesus CMV specific primers amplify a 108-bp amplicon in the
exon 1 region of the immediate-early gene of rhesus CMV [51]
and are reactive with the published AGM CMV [52]. The forward
primer (5-GTTTAGGGAACCGCCATTCTG-3) corresponds to
residues 4847 to 4867 of AGM CMV, the reverse primer (5-
GTATCCGCGTTCCAATGCA-3) corresponds to residues 4936
to 4954, and the probe (5-FAM-TCCAGCCTCCATAGCCGG-
GAAGG-tamra-3) corresponds to residues 4908 to 4930. The
PCR was run on an ABI-Prism 7700 Sequence Detection System
(PerkinElmer, Foster City, CA) [50].
Immunohistochemistry and SIV-specific in situ
hybridization
Nonradioactive in situ hybridization (ISH) for SIV expression
was performed in formalin-fixed, paraffin-embedded lymph nodes
utilizing sense or antisense digoxigenin labeled riboprobes that
spanned the entire SIVagm9063-2 genome as previously described
[25]. The number of SIV-expressing cells was measured as follows:
Six random fields of view were selected for each of the ISH stained
lymph nodes and the AxioVision automated segmentation
measurement program was used to calculate the number of
Figure 10. Impairment of SIVagm-specific antibodies in CD8+ and CD20+ lymphocyte-depleted vervet AGM and PTM. Development of
SIVagm-specific antibody responses by Western blot analysis is shown for CD8+ and CD20+ lymphocyte-depleted vervet AGM (A) and PTM (B) in the
top row. The bottom row shows historic SIVagm-infected vervet AGM (C) and PTM (D) as controls. Numbers below the strips indicate time in weeks
following SIVagmVer90 infection. The location of the major SIV proteins is shown on the right.
doi:10.1371/journal.ppat.1000691.g010
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were also evaluated for CD20 positive cells by using a mouse anti-
human CD20 antibody (M0755, DAKO Cytomation, Carpen-
teria, CA), a mouse IgG avidin biotin complex-peroxidase kit
(Vector Laboratories, Ltd., Burlingame, CA), and diaminobenzi-
dine (DAB) substrate.
Western blot analysis for SIV-specific antibodies
Serology for antibodies to SIVagm was performed by Western
blot analysis, as previously described [25]. Briefly, virus was
pelleted from cell-free supernatant of CEMss cells infected with
SIVagmVer90. Virus particles were disrupted in Laemmli sample
buffer, viral proteins were separated by SDS/polyacrylamide gel
electophoresis and transferred onto nitrocellulose membranes.
Individual strips containing SIVagm viral proteins were reacted
with diluted PTM and AGM plasma and washed to remove
unbound material. The bound SIV specific antibodies were
visualized by subsequent reaction with ImmunoPure A/G protein
conjugated with alkaline phosphatase (Pierce Biotechnology,
Rockford, IL), followed by nitroblue tetrazolium-5-bromo-4-
chloro-3-indolylphosphate (BCIP/NBT) substrate system (KPL,
Laboratories, Gaithersburg, MD).
Serum neutralizing antibody assays
Neutralization was measured as a function of reduction in
luciferase reporter gene expression after a single round of infection
in TZM-bl cells as described [31]. TZM-bl cells were obtained
from the NIH AIDS Research and Reference Reagent Program,
as contributed by John Kappes and Xiaoyun Wu. Briefly, 200
TCID50 of virus was incubated with a serial 3-fold dilution of test
sample in duplicates in a total volume of 150 ml for 1 h at 37uCi n
96-well flat-bottom culture plates. Freshly trypsinized cells (10,000
cells in 100 ml of growth medium containing 75 mg/ml DEAE
dextran) were added to each well. One set of control wells received
cells and virus (virus control) and another set received cells only
(background control). After a 48 h incubation, 100 ml of cells were
transferred to a 96-well black solid plate (Corning, Lowell, MA) for
measurement of luminescence using the Britelite Luminescence
Reporter Gene Assay System (PerkinElmer). Neutralization titers
are the dilution at which relative luminescence units (RLU) were
reduced by 50% compared to virus control wells after subtraction
of background RLUs. Assay stocks of molecularly cloned Env-
pseudotyped viruses were prepared by transfection in 293T cells
and were titrated in TZM-bl cells as described [31].
Monoclonal antibodies and immunophenotyping of
lymphocytes
All antibodies were purchased from BD Biosciences (San Jose,
CA), BD Pharmingen (San Jose, CA), Caltag (Carlsbad, CA),
R&D Systems (Minneapolis, MN) or Beckman Coulter (Miami,
FL). The antibodies used in this study were anti-CD95-
Allophycocyanin (DX2; BD Pharmingen), anti-CD28-PerCP-
Cy5.5 (L293; BD Biosciences), anti-CD4-AmCyan (L200; BD
Biosciences), anti-CD3-Pacific blue (SP34-2; BD Biosciences),
anti-CD3-Alexa Fluor 700 (SP34; BD Pharmingen), anti-CD8a-
Allophycocyanin-Cy7 (SK1; BD Biosciences), anti-CD8a-Phyco-
erythrin (DK25; Dako, Carpenteria, CA), anti-CD8a-PerCP-
Cy5.5 (SK1; BD Biosciences), anti-CD8a-Allophycocyanin (SK1;
BD Biosciences), anti-CD8ab-Energy-Coupled Dye (ECD)
(2ST8.5H7; Beckman Coulter), anti-CD20-Allophycocyanin-Cy7
(L27; BD Biosciences), CD79a-PerCP-Cy5.5 (HM47; BD Phar-
mingen), CD20-Phycoerythrin-Cy7 (L27; BD Biosciences), Ki-67-
Fluorescein Isothiocyanate (B56; BD Biosciences). In order to
determine the efficacy of lymphocyte depletion, whole blood was
stained with anti-CD3, anti-CD4, anti-CD8, anti-CD8ab, anti-
CD20, and anti-CD79a antibodies. The use of the anti-CD8 clone
DK25 (coupled to PE) and anti-CD79a permits detection of CD8+
lymphocytes and B cells with the best sensitivity in lymphocyte-
depleted animals treated with the antibodies cM-T807 and
Rituximab [53,54]. For detection of maturation-associated T cell
subsets, whole blood samples were stained for 15 min with anti-
surface antibodies (CD3, CD4, CD8a, CD8ab, CD28 and CD95).
Red blood cells were lysed by a TQ-prep instrument (Beckman
Coulter) and the cells were washed with PBS. For determination of
proliferation, cells were then fixed and permeabilized with
Cytofix/Cytoperm solution (BD Biosciences) according to the
manufacturer’s description and stained with anti-Ki-67 mAb.
Labeled cells were fixed in 1.5% formaldehyde-phosphate-
Figure 11. CD8+ and CD20+ lymphocyte depletion delays the
generation of neutralizing antibodies in SIVagmVer90-infected
AGM. A neutralizing antibody assay using tissue culture lab-adapted
SIVmac251 was utilized to detect neutralizing Ab in historical control
(black symbols) and CD8+ and CD20+ lymphocyte-depleted SIVagmVer90-
infected vervet AGM (A). Impact of delayed appearance of neutralizing
Ab on set point viremia in two long-term B cell-depleted animals (A346:
B; A13: C).
doi:10.1371/journal.ppat.1000691.g011
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(BD Biosciences) and analyzed using FlowJo software (TreeStar
Inc., Ashland, OR). Mononuclear cells were purified from BAL
samples and lymph node biopsies and viably frozen in media
consisting of 20% DMSO and 80% FCS, and flow cytometry was
performed on thawed suspensions.
Statistical analyses
Statistical analyses and graphical presentations were computed
with GraphPad Prism 5.02 (GraphPad Prism Software, La Jolla,
CA). P values of ,0.05 were considered significant. Mann-
Whitney tests were applied for comparison of two groups. Kaplan-
Meier graphs were used to compare survival, and log-rank tests
were applied for statistical comparison.
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